RUBICON RESEARCH LIMITED
Latest filings
Next results: Thu, 5 Nov · Financial Results- Board meeting set for November 5 to approve September results · Results
- US FDA inspection of Satara facility ends with 1 procedural observation · Regulatory & Legal
- Quarterly dematerialisation compliance certificate filed · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹1,936 Cr over the trailing twelve months.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
RUBICON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from RUBICON RESEARCH LIMITED's filed financials and exchange disclosures
What does RUBICON RESEARCH LIMITED do?
RUBICON RESEARCH LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol RUBICON.
Is RUBICON RESEARCH LIMITED profitable?
Yes. Over the trailing twelve months RUBICON RESEARCH LIMITED reported a net profit of ₹288 Cr on revenue of ₹1,936 Cr.
Does RUBICON RESEARCH LIMITED pay a dividend?
Yes. It paid out 0% of its profit as dividend in FY26.
Is RUBICON RESEARCH LIMITED debt-free?
No. It reported borrowings of ₹259 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹74 Cr after cash. Debt stands at 0.20× equity. That is higher than 58% of its 166 Pharmaceuticals peers.
Is RUBICON RESEARCH LIMITED expensive compared with its peers?
On trailing P/E, RUBICON RESEARCH LIMITED ranks 136 of 158 in Pharmaceuticals — cheaper than 14% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.
How much does the RUBICON RESEARCH LIMITED share price move in a day?
On a typical session RUBICON RESEARCH LIMITED moves 1.41% — that is the median absolute close-to-close move across its last 252 trading days. MarketPing measures each filing's price reaction against it.
When are RUBICON RESEARCH LIMITED's next results?
Financial Results on Thu, 5 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track RUBICON RESEARCH LIMITED's announcements?
Every NSE and BSE filing by RUBICON RESEARCH LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.